GlassScriptPhysician profile
Bruce K Chung
NPI 1124123823
$4,372.25
in general payments reported to CMS, 2019-2025
41 companies · $1,104 in 2025
The $1,104 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $429 · 2020: $412 · 2021: $504 · 2022: $732 · 2023: $674 · 2024: $517 · 2025: $1,104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,295.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $674.46 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $366.01 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $365.19 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Viiv Healthcare Company | $346.54 | 2023-2025 | Apretude |
| Exact Sciences Corporation | $249.52 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Pfizer INC. | $222.34 | 2020-2025 | |
| Bausch Health US, LLC | $151.51 | 2022-2024 | Aplenzin, Wellbutrin |
| Genentech USA, INC. | $150.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $137.20 | 2019-2021 | |
| Hologic Sales and Service, LLC | $135.40 | 2019-2025 | Aptima |
| Phadia US INC. | $121.05 | 2019-2025 | Immunocap |
| Baxter Healthcare | $113.97 | 2023 | Hillrom - Ecg Electrode |
| Medtronic, INC. | $110.96 | 2025 | Interstim |
| Dynavax Technologies Corporation | $109.04 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.52 | 2023-2024 | Xifaxan, Trulance |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $87.43 | 2023-2025 | Azstarys |
| Abbvie INC. | $82.07 | 2022-2024 | Vraylar |
| Merck Sharp & Dohme LLC | $81.06 | 2019-2022 | |
| Amgen INC. | $66.90 | 2019-2024 | Otezla, Repatha |
| Axsome Therapeutics, INC. | $55.18 | 2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $54.52 | 2022-2023 | Qelbree |
| Evofem Biosciences, INC. | $50.84 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $45.89 | 2025 | Contrave |
| Fresenius Kabi USA, LLC | $45.08 | 2025 | |
| Organon LLC | $44.94 | 2022-2023 | Nexplanon |
| Boston Scientific Corporation | $39.26 | 2022 | |
| Tris Pharma INC | $38.74 | 2025 | Dyanavel Xr |
| Sanofi Pasteur INC. | $38.26 | 2021-2022 | |
| Vbi Vaccine (Delaware) INC. | $37.26 | 2022 | |
| Mayne Pharma Commercial LLC | $34.78 | 2025 | |
| Gilead Sciences, INC. | $25.04 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.25 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.33 | 2022 | |
| Intra-Sana Laboratories | $22.87 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Abbott Laboratories | $22.26 | 2024 | Freestyle Libre 3 |
| Alnylam Pharmaceuticals INC. | $20.28 | 2023 | Onpattro |
| Redhill Biopharma INC. | $19.75 | 2020 | |
| Alk-Abello, INC | $18.47 | 2024 | Grastek, Odactra, Ragwitek |
| Insightec,INC | $17.72 | 2025 | Exablate |
| Novo Nordisk INC | $16.86 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $16.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Chung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.